fbpx
Donate

Treatment

View all news
New first line treatment approved for EGFR-patients in Scotland
9th Sep 2019

New first line treatment approved for EGFR-patients in Scotland
SMC rejects targeted therapy as first line treatment
9th Sep 2019

SMC rejects targeted therapy as first line treatment
Take a second look: The importance of rebiopsying
20th Aug 2019

Take a second look: The importance of rebiopsying
NICE rejects targeted therapy as first line treatment
9th Jul 2019

NICE rejects targeted therapy as first line treatment
New life-extending treatment for NHS England patients
5th Jul 2019

New life-extending treatment for NHS England patients
‘Promising’ lung cancer treatment for NSCLC approved.
28th Mar 2019

‘Promising’ lung cancer treatment for NSCLC approved.
NICE approves another treatment option for ALK+ non-small cell lung cancer patients
20th Mar 2019

NICE approves another treatment option for ALK+ non-small cell lung cancer patients
Lifeline for ALK+ patients after new lung cancer treatment approved
21st Feb 2019

Lifeline for ALK+ patients after new lung cancer treatment approved
New lung cancer treatment approved by NICE
22nd Nov 2018

New lung cancer treatment approved by NICE
Alectinib Approved for Scottish Patients
13th Aug 2018

Alectinib Approved for Scottish Patients
Changing Lung Cancer Pathway Reduces Waiting Times and Saves Money
6th Aug 2018

Changing Lung Cancer Pathway Reduces Waiting Times and Saves Money
NICE approves another new treatment option for patients with ALK+ NSCLC
2nd Jul 2018

NICE approves another new treatment option for patients with ALK+ NSCLC
New targeted therapy ‘significant step forward’ for lung cancer patients in Scotland
12th Jun 2018

New targeted therapy ‘significant step forward’ for lung cancer patients in Scotland
Life-lengthening lung cancer drug approved for general commissioning
6th Jun 2018

Life-lengthening lung cancer drug approved for general commissioning
New approved lung cancer treatment is first of its kind
1st Jun 2018

New approved lung cancer treatment is first of its kind